Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease

被引:0
|
作者
Hanzel, J. [1 ]
Sever, N. [1 ]
Ferkolj, I. [1 ]
Stabuc, B. [1 ]
Smrekar, N. [1 ]
Kozelj, M. [1 ]
Novak, G. [1 ]
Gils, A. [2 ]
Drobne, D. [1 ]
机构
[1] Univ Med Ctr Ljubljana, Dept Gastroenterol, Ljubljana, Slovenia
[2] Katholieke Univ Leuven, Lab Pharmaceut Biol, Leuven, Belgium
来源
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P603
引用
收藏
页码:S414 / S414
页数:1
相关论文
共 50 条
  • [21] Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) Patients During Maintenance Therapy
    Ungaro, Ryan
    Jossen, Jacqueline
    Phan, Becky
    Chefitz, Ezra
    Jain, Anjali
    Naik, Snehal
    Dubinsky, Marla
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S7 - S7
  • [22] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [23] Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease
    Buffone, Elisa
    Gupta, Shaan
    Al Ibrahim, Bashaar
    Marshall, John K.
    Halder, Smita
    Tse, Frances
    Albashir, Siwar
    Morgan, David
    Lumb, Barry
    Armstrong, David
    Narula, Neeraj
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2022, 56 (09) : 794 - 797
  • [24] Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Dreesen, E.
    Hoffman, I.
    Ferrante, M.
    Vermeire, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S362 - S363
  • [25] Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab
    Christensen, Britt
    Rubin, David T.
    Goeppinger, Sarah
    Colman, Ruben J.
    Yarur, Andres
    Hirsch, Ayal
    Bocheneck, Ashley
    Wichmann, Alana
    Sakuraba, Atsushi
    Cohen, Russell
    Siddiqui, Dania
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S783 - S784
  • [26] Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis
    Saito, Daisuke
    Matsuura, Minoru
    Ozaki, Ryo
    Tokunaga, Sotaro
    Minowa, Shintaro
    Mitsui, Tatsuya
    Miura, Miki
    Sakuraba, Akihito
    Hayashida, Mari
    Miyoshi, Jun
    Hisamatsu, Tadakazu
    [J]. JGH OPEN, 2021, 5 (09): : 1056 - 1062
  • [27] Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
    Yacoub, W.
    Williet, N.
    Pouillon, L.
    Di-Bernado, T.
    Bittencourt, M. De Carvalho
    Nancey, S.
    Lopez, A.
    Paul, S.
    Zallot, C.
    Roblin, X.
    Peyrin-Biroulet, L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 906 - 912
  • [28] VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang
    Raffals, Laura
    Tremaine, William J.
    Loftus, Edward V., Jr.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S62 - S63
  • [29] VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang
    Raffals, Laura
    Tremaine, William J.
    Loftus, Edward V., Jr.
    [J]. GASTROENTEROLOGY, 2018, 154 (01) : S89 - S89
  • [30] Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective study
    Falzone, M. H.
    Ribaldone, D. G.
    Saracco, G. M.
    Bertani, L.
    Ceccarelli, L.
    Costa, F.
    Bottari, A.
    Fornaroli, G.
    Cusato, J.
    D'Avolio, A.
    Palermiti, A.
    Antonucci, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1216 - I1216